Divisiong of Nephrology and Hypertension




Radko Komers, M.D., Ph.D.

Radko Komers, M.D., Ph.D.
Affiliate Member

Back to faculty page



Radko Komers, M.D., Ph.D.

Dr. Komers joined the Division research staff in March 1998.  His research focus is on diabetes-associated renal disease and factors influencing the progression of renal disease in general. Dr. Komers joined the clinical team in 2010, participating in the hypertension clinics and specializing in diabetic kidney disease.  In 2014, Dr. Komers closed his clinics to focus on his research efforts.  He is currently an Affiliate Member of the Division.

  • M.D. - Charles’ University, Prague, Czech Republic 1979-1985
  • Degree in Internal Medicine, Postgraduate School of Medicine, Prague, Czech Republic, 1988
  • Degree in Diabetology, Postgraduate School of Medicine, Prague, Czech Republic. 1994
  • Ph.D. - Czech Academy of Sciences 4/1996
  • Ph.D. Thesis - The role of endogenous vasoactive factors - nitric oxide, kallikrein-kinin and renin-angiotensin systems in the pathogenesis of diabetic microangiopathy

Internal Medicine – Institute for clinical and Experimental Medicine, Prague, Czech Republic, 1985-1988


Research Fellow - Department of Medicine, University of Melbourne, Austin and Repatriation Hospitals, Heidelberg West, Victoria, Australia.

  • Role of endogenous vasodilators in the pathophysiology of early renal hemodynamic changes in diabetic nephropathy Pathophysiology of the diabetes-associated vascular hypertrophy. Renal physiology of amylin. 4/1992 - 5/1994
Research Interest:

Diabetic kidney disease, role of endogenous vasoactive factors in the control of blood pressure and renal function.

Representative Publications:
  • Komers R, Allen TJ and Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 43: 1190-1197, 1994
  • Komers R, Cooper ME. Acute renal hemodynamic effects of angiotensin converting enzyme inhibition in diabetic hyperfiltration: The role of kinins. Am J Physiol 268: F588-F594, 1995
  • Rumble JR, Komers R, Cooper ME. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 14: 601-7, 1996
  • Komers R, Cooper ME. Renal sodium handling in experimental diabetes: Role of NO. Nephrol Dial Transplant 11: 2170-2177, 1996
  • Komers R, Komersova K, Kazdova L, Ruzickova J, Pelikanova T. Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans. J Hypertension 18:51-9, 2000
  • Komers R, Oyama TT, Chapman JG, Allison KM, Anderson S. Effects of systemic inhibition of neuronal nitric oxide synthase (NOS1) in diabetic rats. Hypertension 35:655-61, 2000
  • Komers R, Anderson S. Are ACE inhibitors the best treatment of hypertension in Type 2 diabetes? Current Opinion in Nephrology and Hypertension 9: 173-179, 2000
    Komers R, Lindsley JN, Oyama TT, Anderson S. Renal effects of inhibition of neuronal NOS (NOS1) in control and diabetic rats. Am J Physiol 2000, 279(3):F573-583.
  • Komers R, Jessie N. Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader S, and Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107: 889-898, 2001
  • Komers R, Anderson S , Meyer T. Pathophysiology and Nephron Adaptation in Chronic Renal Failure. In: Diseases of the Kidney, Schrier RW ed.,Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2001